These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11310602)

  • 1. Synthesis of [18F]-labeled EF3 [2-(2-nitroimidazol-1-yl)-N-(3,3,3-trifluoropropyl)-acetamide], a marker for PET detection of hypoxia.
    Josse O; Labar D; Georges B; Grégoire V; Marchand-Brynaert J
    Bioorg Med Chem; 2001 Mar; 9(3):665-75. PubMed ID: 11310602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of new hypoxia markers EF1 and [18F]-EF1.
    Kachur AV; Dolbier WR; Evans SM; Shiue CY; Shiue GG; Skov KA; Baird IR; James BR; Li AR; Roche A; Koch CJ
    Appl Radiat Isot; 1999 Dec; 51(6):643-50. PubMed ID: 10581679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perfluorinated markers for hypoxia detection: synthesis of sulfur-containing precursors and [18F]-labelling.
    Cheguillaume A; Gillart J; Labar D; Grégoire V; Marchand-Brynaert J
    Bioorg Med Chem; 2005 Feb; 13(4):1357-67. PubMed ID: 15670943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [18F]-EF5, a marker for PET detection of hypoxia: synthesis of precursor and a new fluorination procedure.
    Dolbier WR; Li AR; Koch CJ; Shiue CY; Kachur AV
    Appl Radiat Isot; 2001 Jan; 54(1):73-80. PubMed ID: 11144255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis of [18F]fluoroetanidazole: a potential new tracer for imaging hypoxia.
    Tewson TJ
    Nucl Med Biol; 1997 Nov; 24(8):755-60. PubMed ID: 9428602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Development of [18F]FRP-170 injection for imaging hypoxia by PET].
    Ishikawa Y; Funaki Y; Iwata R; Furumoto S; Nakata E; Kudo Y; Kaneta T; Hakamatsuka T; Takai Y; Yamada S
    Kaku Igaku; 2005 Feb; 42(1):1-10. PubMed ID: 15794116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depletion of tumor oxygenation during photodynamic therapy: detection by the hypoxia marker EF3 [2-(2-nitroimidazol-1[H]-yl)-N-(3,3,3-trifluoropropyl)acetamide ].
    Busch TM; Hahn SM; Evans SM; Koch CJ
    Cancer Res; 2000 May; 60(10):2636-42. PubMed ID: 10825135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical validation of the hypoxia tracer 2-(2-nitroimidazol-1-yl)- N-(3,3,3-[(18)F]trifluoropropyl)acetamide, [(18)F]EF3.
    Mahy P; De Bast M; Leveque PH; Gillart J; Labar D; Marchand J; Gregoire V
    Eur J Nucl Med Mol Imaging; 2004 Sep; 31(9):1263-72. PubMed ID: 15197503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A robotic synthesis of [18F]fluoromisonidazole ([18F]FMISO).
    Chang CW; Chou TK; Liu RS; Wang SJ; Lin WJ; Chen CH; Wang HE
    Appl Radiat Isot; 2007 Jun; 65(6):682-6. PubMed ID: 17379530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of tumour hypoxia with the PET tracer [18F]EF3: improvement of the tumour-to-background ratio in a mouse tumour model.
    Christian N; Bol A; De Bast M; Labar D; Lee J; Mahy P; Grégoire V
    Eur J Nucl Med Mol Imaging; 2007 Sep; 34(9):1348-54. PubMed ID: 17334763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adduct of 2-[18F]FDG and 2-nitroimidazole as a putative radiotracer for the detection of hypoxia with PET: synthesis, in vitro- and in vivo-characterization.
    Patt M; Sorger D; Scheunemann M; Stöcklin G
    Appl Radiat Isot; 2002 Nov; 57(5):705-12. PubMed ID: 12433045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of a new [18F]fluoropyridine-based haloacetamide reagent for the labeling of oligonucleotides: 2-bromo-N-[3-(2-[18F]fluoropyridin-3-yloxy)propyl]acetamide.
    Kuhnast B; de Bruin B; Hinnen F; Tavitian B; Dollé F
    Bioconjug Chem; 2004; 15(3):617-27. PubMed ID: 15149190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positron emission tomography radiotracers for imaging hypoxia.
    Wuest M; Wuest F
    J Labelled Comp Radiopharm; 2013; 56(3-4):244-50. PubMed ID: 24285331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of hypoxia by [18F]EF5 in atherosclerotic plaques in mice.
    Silvola JM; Saraste A; Forsback S; Laine VJ; Saukko P; Heinonen SE; Ylä-Herttuala S; Roivainen A; Knuuti J
    Arterioscler Thromb Vasc Biol; 2011 May; 31(5):1011-5. PubMed ID: 21372297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simple, column purification technique for the fully automated radiosynthesis of [18F]fluoroazomycinarabinoside ([18F]FAZA).
    Nandy SK; Rajan MG
    Appl Radiat Isot; 2010 Oct; 68(10):1944-9. PubMed ID: 20478712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of [18F]FETNIM: a potential marker for PET.
    Grönroos T; Eskola O; Lehtiö K; Minn H; Marjamäki P; Bergman J; Haaparanta M; Forsback S; Solin O
    J Nucl Med; 2001 Sep; 42(9):1397-404. PubMed ID: 11535732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1-[3-(2-[18F]fluoropyridin-3-yloxy)propyl]pyrrole-2,5-dione: design, synthesis, and radiosynthesis of a new [18F]fluoropyridine-based maleimide reagent for the labeling of peptides and proteins.
    de Bruin B; Kuhnast B; Hinnen F; Yaouancq L; Amessou M; Johannes L; Samson A; Boisgard R; Tavitian B; Dollé F
    Bioconjug Chem; 2005; 16(2):406-20. PubMed ID: 15769096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiosynthesis of [18F] N-3-fluoropropyl-2-beta-carbomethoxy-3-beta (4' methylphenyl) nortropane (FPCMT).
    Chaly T; Matacchieri R; Dahl R; Dhawan V; Eidelberg D
    Appl Radiat Isot; 1999 Sep; 51(3):299-305. PubMed ID: 10404612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative pharmacokinetics, biodistribution, metabolism and hypoxia-dependent uptake of [18F]-EF3 and [18F]-MISO in rodent tumor models.
    Mahy P; De Bast M; de Groot T; Cheguillaume A; Gillart J; Haustermans K; Labar D; Grégoire V
    Radiother Oncol; 2008 Dec; 89(3):353-60. PubMed ID: 18649964
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.